Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. The company is headquartered in New York City, New York and currently employs 362 full-time employees. The company went IPO on 2019-05-14. The firm is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. The company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Follow-Up Questions
¿Quién es el CEO de Immunovant Inc?
Dr. Eric Venker es el Chief Executive Officer de Immunovant Inc, se unió a la empresa desde 2020.
¿Qué tal es el rendimiento del precio de la acción IMVT?
El precio actual de IMVT es de $25.21, ha increased un 2.15% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Immunovant Inc?
Immunovant Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Immunovant Inc?
La capitalización bursátil actual de Immunovant Inc es $4.3B
¿Es Immunovant Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 16 analistas han realizado calificaciones de análisis para Immunovant Inc, incluyendo 8 fuerte compra, 9 compra, 5 mantener, 0 venta, y 8 fuerte venta
